Opinion|Videos|January 21, 2025
Key Differences in T-Cell Response Therapy vs CAR T Therapy
A panelist discusses how T-cell receptor (TCR) therapy offers potential advantages over chimeric antigen receptor (CAR) T therapy in solid tumors due to its ability to recognize intracellular antigens through human leukocyte antigen (HLA) presentation and its generally better safety profile with lower cytokine release syndrome rates, though TCR therapy faces its own challenges, including HLA restriction and potential cross-reactivity risks.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the key differences between TCR technology vs CAR T technology in this space? (Focusing on the differences in safety profiles seen in TCR and the ability to work well in solid tumors where CAR T has struggled)
Advertisement
Related to this article
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
5